ABN 82 010 975 612



Level 18, 101 Collins Street Victoria 3000 Australia Telephone: + 61 7 3273 9133 Facsimile: + 61 7 3375 1168 www.tbgbio.com

5 May 2020

ASX Announcement Update on TBG Xiamen COVID-19 Virus Diagnostic Test Kit

TBG Diagnostics Limited ("Company") advises that the Company has received notification from TBG Biotechnology Xiamen Inc. ("TBG Xiamen") that the Chinese Department of Commerce has lifted the bans restricting the exportation of TBG Xiamen's CE Marked COVID-19 Nucleic Acid Test Kits.

As previously announced, TBG Xiamen have received CE Mark approval for its COVID-19 Nucleic Acid Diagnostics Kit. Following the lift of the export ban the COVID-19 Nucleic Acid Test Kits are now able to be exported from China for sale throughout the European Economic Area subject to individual countries accepting import of the test kit.

The Company has a 46.65% interest in the equity of TBG Xiamen, which is a China based molecular diagnostics company.

Jitto Arulampalam Chairman On behalf of the Board of Directors TBG Diagnostics Limited